Downregulation of microRNA‑629‑5p in colorectal cancer and prevention of the malignant phenotype by direct targeting of low‑density lipoprotein receptor‑related protein 6 Retraction in /10.3892/ijmm.2021.5057

Yan,Guoqiang; Li,Chenyao; Zhao,Yuhang; Yue,Meng; Wang,Lei

doi:10.3892/ijmm.2019.4245

Downregulation of microRNA‑629‑5p in colorectal cancer and prevention of the malignant phenotype by direct targeting of low‑density lipoprotein receptor‑related protein 6

Retraction in: /10.3892/ijmm.2021.5057

Authors:
- Guoqiang Yan
- Chenyao Li
- Yuhang Zhao
- Meng Yue
- Lei Wang
View Affiliations

Affiliations: Department of Colorectal and Anal Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: June 18, 2019 https://doi.org/10.3892/ijmm.2019.4245
Pages: 1139-1150

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Aberrant expression of numerous microRNAs (miRNAs/miRs) in colorectal cancer (CRC) significantly affects disease progression. Recently, miR‑629‑5p (miR‑629) was identified as a tumor‑promoting miRNA in the malignant processes of a number of human cancers. However, few studies have been conducted regarding expression profiles and detailed roles of miR‑629 in CRC. In the present study, reverse transcription‑quantitative polymerase chain reaction was used to assess miR‑629 expression in CRC tissues and cell lines. Cell Counting Kit‑8 assay, flow cytometry and Transwell assays were performed to determine the in vitro effects of miR‑629 on CRC cell proliferation, apoptosis, and metastasis, respectively. Xenograft models were employed to determine the in vivo effects of miR‑629 on tumor growth in nude mice. Molecular mechanisms underlying the activity of miR‑629 in CRC cells were explored. miR‑629 expression decreased in CRC tissues and cell lines. The decreased aberrant miR‑629 expression was significantly associated with tumor size, lymphatic metastasis and tumor‑node‑metastasis stage of CRC, and was a predictor of poor prognosis. Restoring miR‑629 expression attenuated CRC cell proliferation, migration and invasion; promoted cell apoptosis in vitro; and inhibited tumor growth in vivo. Low‑density lipoprotein receptor‑related protein 6 (LRP6) was a direct target gene of miR‑629 in CRC cells. Furthermore, the effect of LRP6 knockdown was similar to that of miR‑629 overexpression in CRC cells. Restoration of LRP6 expression neutralized the effects of miR‑629 in CRC cells. miR‑629 suppressed the activation of the Wnt/β‑catenin pathway through LRP6 regulation both in vitro and in vivo. In conclusion, miR‑629 suppressed the development and progression of CRC by directly targeting LRP6 and inhibiting the Wnt/β‑catenin pathway both in vitro and in vivo. Therefore, miR‑629 may be a novel prognostic biomarker and therapeutic target in CRC.

View Figures

View References

1	Tenesa A and Dunlop MG: New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat Rev Genet. 10:353–358. 2009. View Article : Google Scholar : PubMed/NCBI
2	Brenner H, Kloor M and Pox CP: Colorectal cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar
3	Labianca R and Merelli B: Screening and diagnosis for colorectal cancer: Present and future. Tumori. 96:889–901. 2010. View Article : Google Scholar
4	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar
5	Haggar FA and Boushey RP: Colorectal cancer epidemiology: Incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 22:191–197. 2009. View Article : Google Scholar :
6	Center MM, Jemal A, Smith RA and Ward E: Worldwide variations in colorectal cancer. CA Cancer J Clin. 59:366–378. 2009. View Article : Google Scholar : PubMed/NCBI
7	Lo Russo G, Tessari A, Capece M, Galli G, de Braud F, Garassino MC and Palmieri D: MicroRNAs for the diagnosis and management of malignant pleural mesothelioma: A literature review. Front Oncol. 8:6502018. View Article : Google Scholar
8	Mollaei H, Safaralizadeh R and Rostami Z: MicroRNA replacement therapy in cancer. J Cell Physiol. 234:12369–12384. 2019. View Article : Google Scholar : PubMed/NCBI
9	Ors-Kumoglu G, Gulce-Iz S and Biray-Avci C: Therapeutic microRNAs in human cancer. Cytotechnology. 71:411–425. 2019. View Article : Google Scholar : PubMed/NCBI
10	Kala R, Peek GW, Hardy TM and Tollefsbol TO: MicroRNAs: An emerging science in cancer epigenetics. J Clin Bioinforma. 3:62013. View Article : Google Scholar : PubMed/NCBI
11	Stark A, Brennecke J, Bushati N, Russell RB and Cohen SM: Animal MicroRNAs confer robustness to gene expression and have a significant impact on 3′UTR evolution. Cell. 123:1133–1146. 2005. View Article : Google Scholar : PubMed/NCBI
12	Hede K: Studies define role of microRNA in cancer. J Natl Cancer Inst. 97:1114–1115. 2005. View Article : Google Scholar : PubMed/NCBI
13	Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A and Enright AJ: miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 34(Database Issue): D140–D144. 2006. View Article : Google Scholar :
14	Huang S, Tan X, Huang Z, Chen Z, Lin P and Fu SW: microRNA biomarkers in colorectal cancer liver metastasis. J Cancer. 9:3867–3873. 2018. View Article : Google Scholar : PubMed/NCBI
15	Ding L, Lan Z and Xiong X: The dual role of micrornas in colorectal cancer progression. Int J Mol Sci. 19:pii: E2791. 2018. View Article : Google Scholar
16	Yang S, Sun Z, Zhou Q, Wang W, Wang G, Song J, Li Z, Zhang Z, Chang Y, Xia K, et al: MicroRNAs, long noncoding RNAs, and circular RNAs: Potential tumor biomarkers and targets for colorectal cancer. Cancer Manag Res. 10:2249–2257. 2018. View Article : Google Scholar : PubMed/NCBI
17	Wang J, Song C, Tang H, Tang H, Zhang C, Tang J, Li X, Chen B and Xie X: miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer. Breast Cancer Res. 19:722017. View Article : Google Scholar : PubMed/NCBI
18	Zhang X, Luo P, Jing W, Zhou H, Liang C and Tu J: circSMAD2 inhibits the epithelial-mesenchymal transition by targeting miR-629 in hepatocellular carcinoma. Onco Targets Ther. 11:2853–2863. 2018. View Article : Google Scholar : PubMed/NCBI
19	Zheng YQ, Bai YF, Yang S, Cui YR, Wang YP and Hu WL: MircoRNA-629 promotes proliferation, invasion and migration of nasopharyngeal carcinoma through targeting PDCD4. Eur Rev Med Pharmacol Sci. 23:207–216. 2019.PubMed/NCBI
20	Phuah NH, Azmi MN, Awang K and Nagoor NH: Suppression of microRNA-629 enhances sensitivity of cervical cancer cells to 1′S-1′-acetoxychavicol acetate via regulating RSU1. Onco Targets Ther. 10:1695–1705. 2017. View Article : Google Scholar :
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
22	Peröbner I, Karow M, Jochum M and Neth P: LRP6 mediates Wnt/β-catenin signaling and regulates adipogenic differentiation in human mesenchymal stem cells. Int J Biochem Cell Biol. 44:1970–1982. 2012. View Article : Google Scholar
23	Lemieux E, Cagnol S, Beaudry K, Carrier J and Rivard N: Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer. Oncogene. 34:4914–4927. 2015. View Article : Google Scholar
24	Yang X, Wang L, Wang Q, Li L, Fu Y and Sun J: MiR-183 inhibits osteosarcoma cell growth and invasion by regulating LRP6-Wnt/β-catenin signaling pathway. Biochem Biophys Res Commun. 496:1197–1203. 2018. View Article : Google Scholar : PubMed/NCBI
25	Shirafkan N, Mansoori B, Mohammadi A, Shomali N, Ghasbi M and Baradaran B: MicroRNAs as novel biomarkers for colorectal cancer: New outlooks. Biomed Pharmacother. 97:1319–1330. 2018. View Article : Google Scholar
26	Masuda T, Hayashi N, Kuroda Y, Ito S, Eguchi H and Mimori K: MicroRNAs as biomarkers in colorectal cancer. Cancers (Basel). 9:pii: E124. 2017. View Article : Google Scholar
27	Sarvizadeh M, Malekshahi ZV, Razi E, Sharifi H, Moussavi N and Taghizadeh M: MicroRNA: A new player in response to therapy for colorectal cancer. J Cell Physiol. 234:8533–8540. 2019. View Article : Google Scholar
28	Balacescu O, Sur D, Cainap C, Visan S, Cruceriu D, Manzat-Saplacan R, Muresan MS, Balacescu L, Lisencu C and Irimie A: The impact of miRNA in colorectal cancer progression and its liver metastases. Int J Mol Sci. 19:pii: E3711. 2018. View Article : Google Scholar : PubMed/NCBI
29	Shao L, Shen Z, Qian H, Zhou S and Chen Y: Knockdown of miR-629 inhibits ovarian cancer malignant behaviors by targeting testis-specific Y-like protein 5. DNA Cell Biol. 36:1108–1116. 2017. View Article : Google Scholar : PubMed/NCBI
30	Jingushi K, Ueda Y, Kitae K, Hase H, Egawa H, Ohshio I, Kawakami R, Kashiwagi Y, Tsukada Y, Kobayashi T, et al: miR-629 Targets TRIM33 to promote TGFβ/Smad signaling and metastatic phenotypes in ccRCC. Mol Cancer Res. 13:565–574. 2015. View Article : Google Scholar
31	Yan H, Li Q, Wu J, Hu W, Jiang J, Shi L, Yang X, Zhu D, Ji M and Wu C: MiR-629 promotes human pancreatic cancer progression by targeting FOXO3. Cell Death Dis. 8:e31542017. View Article : Google Scholar : PubMed/NCBI
32	Liu CC, Prior J, Piwnica-Worms D and Bu G: LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy. Proc Natl Acad Sci USA. 107:5136–5141. 2010. View Article : Google Scholar : PubMed/NCBI
33	Yuan Y, Xie X, Jiang Y, Wei Z, Wang P, Chen F, Li X, Sun C, Zhao H, Zeng X, et al: LRP6 is identified as a potential prognostic marker for oral squamous cell carcinoma via MALDI-IMS. Cell Death Dis. 8:e30352017. View Article : Google Scholar : PubMed/NCBI
34	Wen Q, Zhao J, Bai L, Wang T, Zhang H and Ma Q: miR-126 inhibits papillary thyroid carcinoma growth by targeting LRP6. Oncol Rep. 34:2202–2210. 2015. View Article : Google Scholar : PubMed/NCBI
35	Du C, Lv Z, Cao L, Ding C, Gyabaah OA, Xie H, Zhou L, Wu J and Zheng S: MiR-126-3p suppresses tumor metastasis and angiogenesis of hepatocellular carcinoma by targeting LRP6 and PIK3R2. J Transl Med. 12:2592014. View Article : Google Scholar : PubMed/NCBI
36	Bhanot P, Brink M, Samos CH, Hsieh JC, Wang Y, Macke JP, Andrew D, Nathans J and Nusse R: A new member of the frizzled family from Drosophila functions as a Wingless receptor. Nature. 382:225–230. 1996. View Article : Google Scholar : PubMed/NCBI
37	Yang C, Yao C, Tian R, Zhu Z, Zhao L, Li P, Chen H, Huang Y, Zhi E, Gong Y, et al: miR-202-3p regulates sertoli cell proliferation, synthesis function, and apoptosis by targeting LRP6 and Cyclin D1 of Wnt/β-catenin signaling. Mol Ther Nucleic Acids. 14:1–19. 2019. View Article : Google Scholar
38	Rismani E, Fazeli MS, Mahmoodzadeh H, Movassagh A, Azami S, Karimipoor M and Teimoori-Toolabi L: Pattern of LRP6 gene expression in tumoral tissues of colorectal cancer. Cancer Biomark. 19:151–159. 2017. View Article : Google Scholar : PubMed/NCBI
39	Yao Q, An Y, Hou W, Cao YN, Yao MF, Ma NN, Hou L, Zhang H, Liu HJ and Zhang B: LRP6 promotes invasion and metastasis of colorectal cancer through cytoskeleton dynamics. Oncotarget. 8:109632–109645. 2017. View Article : Google Scholar